(Circulation. 1997;96:3681-3686.)
© 1997 American Heart Association, Inc.
Articles |
Etomoxir Improves Left Ventricular Performance of Pressure-Overloaded Rat Heart
From the Institute of Pathophysiology, Medical School, Comenius University, Bratislava, Slovak Republic, and Molecular Cardiology Lab, Division of Cardiology, Philipps University of Marburg (Germany).
Correspondence to Marian Turcani, MD, Institute of Pathophysiology, Medical School, Comenius University, Sasinkova 4, 811 08 Bratislava, Slovak Republic. E-mail turcani{at}medik.fmed.uniba.sk
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background Numerous studies have demonstrated diverse abnormalities in subcellular structures of pressure-overloaded hypertrophied and failing heart. Long-term administration of etomoxir, a carnitine palmitoyltransferase-1 inhibitor, partially normalized the proportion of myosin isozyme V1 and number of active Ca2+ pumps in hypertrophied rat myocardium.
Methods and Results To test the hypothesis that long-term etomoxir treatment improves the performance of hypertrophied ventricle, sham-operated rats and rats with ascending aorta constriction were treated with racemic etomoxir (15 mg/kg per day) for 12 weeks. Left ventricular geometry, dynamics of isovolumic contractions, as well as myosin isozymes as marker of etomoxir-induced phenotype changes were assessed. Etomoxir stimulated (P<.05) slight hypertrophic growth in right and left ventricles of sham-operated rats as well as in right ventricles but not in overloaded left ventricles of rats with aortic constriction. In all treated rats, etomoxir increased (P<.05) maximal developed pressure, left ventricular pressure-volume area, and ±dP/dtmax. Enhanced values (P<.05) of derived indexes of myocardial performance (normalized stress-length area, maximal rate of wall stress rise, and decline) indicated that myocardial changes were responsible for the improved performance. The etomoxir treatment increased selectively (P<.05) the proportion of myosin V1 in pressure-overloaded left ventricles.
Conclusions The long-term treatment with etomoxir improved functional capacity of pressure-overloaded left ventricle, which can be attributed to an enhanced myocardial performance. Chronic carnitine palmitoyltransferase-1 inhibition may thus represent a candidate approach for developing novel agents that are useful in the prevention of undesirable consequences of pressure overload–induced cardiac hypertrophy.
Key Words: etomoxir • heart failure • hypertrophy • ventricular function • myosin isozymes
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Current drug treatments of the failing heart syndrome are targeted primarily at the peripheral consequences of pump failure or modulate acutely ion homeostasis of the heart muscle cell. Since various subcellular organelles are altered in hypertrophied and failing heart, the question arises whether the poor life expectancy of patients with left ventricular dysfunction could be improved by preventing changes in molecular structures of overloaded cardiomyocytes.1 However, it remains undefined which features of hypertrophied myocardium should be modified to prevent development of heart failure and what type of pharmacological intervention could be useful.
The isoform switch in myosin heavy chain (MHC) expression during the
development of heart hypertrophy and failure was the first
identified molecular change in overloaded myocardium and
the first example of the reactivation of genes that are normally
expressed during embryonic development.2 3 Preferential
ß-MHC synthesis is, however, only one feature of the myocardial
hypertrophic response, which involves expression of other embryonic
markers as well as quantitative and qualitative changes in expression
of genes encoding various contractile and noncontractile
proteins.4 Some changes in gene expression are transient,
for example, induction of expression of immediate early
genes,4 whereas others such as the decrease in
sarcoplasmic reticulum (SR) Ca2+-ATPase expression are
detected only at later stages.5 ß-MHC mRNA begins to
accumulate with the onset of overload-induced hypertrophy
and remains elevated as long as the load persists.3
Activation of the ß-MHC gene and a deactivation 
-MHC gene could
thus be considered a hallmark of phenotype alterations in
overloaded rat heart. The isoform switch in MHC expression occurs in
all cardiac tissues and species tested.6 However, the
capacity to increase the ß-MHC proportion depends on the initial
phenotype. This capacity is high in rat ventricles and in human
atria, which express preferentially -MHC but is low in human
ventricles with mainly ß-MHC.
Functional consequences of different myosin phenotypes are
still not entirely understood. The change from -MHC to ß-MHC
results in a lower myosin ATPase activity and reduced shortening
velocity.7 This isoform shift, by slowing cross-bridge
cycling, reduces myocardial contractility. However, the
preferential synthesis of ß-MHC improves the mechanical
efficiency of the overloaded heart.8 Thus although
expression of ß-MHC gene has a negative inotropic effect, it is also
energy sparing.9
The well-documented potential of thyroid hormone to increase myocardial
contractility and -MHC synthesis10
resulted in the successful approach of improving the function of
infarcted rat ventricle with L-thyroxin11 as
well as thyroid hormone analogues that are deficient in positive
chronotropic effects.12 Recently, it has been shown that
etomoxir, a carnitine palmitoyltransferase-1 (CPT-1)
inhibitor, influences myosin isoenzyme distribution and
expression of SR Ca2+-ATPase similar to thyroid hormone. In
rats, long-term treatment with etomoxir induced cardiac
hypertrophy, redistributed the myosin isozyme population
from V3 to V1, and increased SR
Ca2+ pump activity.13 14 15 16 17 However, it remained
unresolved whether the shift in myosin isozymes was associated with an
altered performance of pressure-overloaded rat ventricles.
To address this question, rats with constriction of the ascending aorta were treated with etomoxir. Left ventricular performance of isovolumically beating hypertrophied hearts was assessed 12 weeks after inducing hemodynamic overload as well as the etomoxir treatment. The approach permits a load-independent evaluation and comparison of left ventricular and myocardial function despite alterations that occur in cardiac mass, geometry, and myocardial contractility.18 To examine whether changes in myocardial performance could be accounted for by an altered MHC expression, the myosin isozyme population was assessed at the protein level. The study demonstrates that long-term treatment with etomoxir improves the functional capacity of pressure-overloaded rat left ventricle that was attributed to an enhanced myocardial performance. Chronic CPT-1 inhibition may thus represent a candidate approach for developing novel agents that are useful in the prevention of undesirable consequences of pressure overload– induced cardiac hypertrophy.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Animal Model
Male 3-week-old Wistar/WU rats were purchased from Charles-River (Kissleg, Germany) and housed at 21° to 23°C on 12:12-hour light-dark cycle. The rats had free access to tap water and regular chow (Ssniff of Plange). Handling of animals and all experimental procedures were in accordance with the Institutional Guidelines of the University of Tübingen (Germany).
The ascending aorta was banded with a 3-0 silk suture ligature tied against an 0.8-mm blunt steel wire at a body weight of 90 to 100 g under Hypnorm (fluanisone/fentanyl-dihydrogencitrate) anesthesia (1 ml/kg IP). The wire was removed, whereby the aorta was constricted to 60% to 70% of the original diameter. After 12 weeks, the mean left ventricular aortic pressure gradient was 87±4 mm Hg, with no significant difference between etomoxir-treated and nontreated animals. Ascending aortic constriction was performed in 28 rats, 14 rats remained untreated, and 14 rats were treated daily with 15 mg/kg body wt racemic etomoxir starting 1 day after surgery. Age-matched control animals underwent a right thoracotomy, and the ascending aorta was isolated but not constricted. Starting 1 day after surgery, 14 sham-operated rats received 15 mg/kg per day racemic etomoxir and 14 sham-operated rats remained without treatment. Etomoxir was generously provided by Dr H.P.O. Wolf of Byk Gulden, Konstanz, Germany, and was given in the drinking water. The dose was maintained by monitoring the daily water consumption and body weight.
Measurement of Left Ventricular Isovolumic
Contraction
Animals were studied 12 weeks after surgery. The measurements
were performed in open-chest rats under urethane anesthesia
(1.2 g/kg body wt IP) as described previously.18 19
A mediosternal thoracotomy was performed and the left ventricle was
pierced at the apex with a steel cannula No. 1 connected to a
Gould-Statham P23XL pressure transducer (Gould Electronics). The right
carotid artery was cannulated with a polyethylene tubing (0.5-mm inner
diameter) and forwarded to the aortic arch. The tubing was connected to
a second Gould-Statham P23XL pressure transducer. Left
ventricular pressure, left ventricular
diastolic pressure (high amplification of left
ventricular pressure), time derivative of
ventricular pressure (dP/dt), and aortic pressure were
recorded simultaneously on a Hellige Recomed
recording system.
For monitoring isovolumic contractions, the ascending aorta was clamped above the aortic valve for 6 to 8 seconds with a forceps, as verified by the absence of pulsatile pressure in the aortic arch. Small end-diastolic volumes, that is, low preload values, were achieved by a short tightening of a string around the inferior vena cava. The preload increased gradually after relieving the inferior vena cava flow during clamping of the aorta. This procedure was repeated four to six times. The functional analysis was based on the recording exhibiting the highest systolic pressures development.
Left ventricular passive pressure-volume relations were assessed after recording isovolumic contractions. The atrioventricular groove was ligated with a silk string, and the right ventricle was emptied by incision. The left ventricle was filled with a defined volume of saline and emptied in 50-µL steps while recording the passive left ventricular pressure. Three reproducible pressure-volume curves were generated within 3 to 4 minutes after the ligation. No effects of anoxia on the pressure-volume relation could be detected within this period of time. Using the passive pressure-volume relation, end-diastolic cavity volumes required for further analysis were derived from the measured end-diastolic pressures.
Data Analysis
The approach permitted the construction of complete left
ventricular pressure-volume and stress-length diagrams.
Left ventricular and myocardial function were thus assessed
independent of left ventricular mass, geometry, and loading
conditions.18 Systolic peak pressures that are
equivalent to end-systolic pressures under the isovolumic
conditions were plotted against end-diastolic volumes
resulting in end-systolic pressure-volume curves. All auxotonic
pressure-volume values had to reside within this isovolumically
determined end-systolic pressure-volume relation. Thus the area
between end-systolic and end-diastolic
pressure-volume curves up to maximum end-systolic pressure was
used as an index of left ventricular working capacity.
Transformation of the left ventricular pressure-volume
diagram to the stress-length relation permitted the evaluation of
myocardial performance when left ventricular mass
and geometry are altered. Myocardial contractility was
evaluated on the basis of normalized stress-length area, that is, the
area between the end-systolic and end-diastolic
mean wall stress versus normalized midwall circumference (length)
curves. In analogy with papillary muscle, the normalized midwall
circumference was calculated as the ratio between a given midwall
circumference and the midwall circumference associated with peak
developed wall stress.18 Pressure-volume data were
transformed into stress-length data using a thick-walled spherical
shell. Since calculations assumed that the specific density of
myocardium was 1 g/cm3, left
ventricular weight in grams equaled the
ventricular wall volume in cm3.
Mean (systolic or diastolic) wall stress
(
) was derived from the following formula20 :
=P/{[(V+W)/V]2/3-1}, where P is left
intraventricular pressure, V is left
ventricular cavity volume, W is left
ventricular wall volume. Since the contraction was
isovolumic, end-diastolic volume derived from the passive
pressure-volume curve was identical with the left
ventricular cavity volume (V) during the respective beat.
Midwall circumference (CR) was calculated according
to
CR=
{(3/4)1/3[(V1/3+(V+W)1/3]}.
To evaluate the velocity of contraction and relaxation at the
myocardial level, rate of mean wall stress rise (+d/dt) or decline
(-d/dt) was calculated using the recorded ±dP/dt values by
±d/dt=±(dP/dt)/{[(V+W)/V]2/3-1}.
Myosin Isozymes
The proportion of myosin isozymes was determined by
nondissociating polyacrylamide gel electrophoresis in the
presence of pyrophosphate.13 Portions (30 to 50 mg) of the
left ventricle frozen in liquid nitrogen were used. The myosin isozymes
were stained with Coomassie brilliant blue R250 and the gels were
scanned using a Quick Scan densitometer (Helena Laboratories). The
isozymes V1, V2, V3 were
quantitated by measuring peak heights. -MHC was calculated using the
equation
 |
Statistical Analysis
Normality of distribution was checked by the
Kolmogoroff-Smirnoff test and equality of variances according to
Cochran. Multiple comparisons were made by one-way and two-way ANOVA
and the post hoc Newman-Keuls test (Statistica/w, Statsoft).
Statistical significance was assumed at P<.05.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Treatment with racemic etomoxir (15 mg/kg per day) induced slight hypertrophy of both left and right ventricles in sham-operated rats as well as right ventricles of rats with aortic constriction (Table 1
). The aortic
constriction resulted in a concentric remodelling of the left ventricle
(Table 1). The main effect (two-way ANOVA) of aortic constriction and
of etomoxir treatment was to increase developed pressures, left
ventricular pressure-volume areas, as well as positive and
negative dP/dtmax (Figs 1 and 2 and Table 1). There were no significant
interactions, that is, the effects were additive, between pressure
overload and etomoxir treatment for these parameters,
except for -dP/dtmax. The etomoxir-induced increase in
-dP/dtmax values was significantly more pronounced in rats
with aortic constriction than in sham-operated rats. When compared with
untreated rats with pressure overload, etomoxir-treated rats with
aortic constriction exhibited a significant improvement in developed
pressures (Fig 1A), left ventricular pressure-volume areas
(Table 1), as well as ±dP/dtmax values (Fig 2A and B).
|
|
, Untreated
sham-operated control rats; 
, etomoxir-treated sham-operated
rats; 
, untreated rats with aortic constriction; 
,
etomoxir-treated rats with aortic constriction; —,
end-systolic pressure-volume relations; and ----, passive
(diastolic) pressure-volume relations. *P<.05
compared with sham-operated untreated rats, 
P<.05
compared with untreated rats with aortic constriction.
|
An increase in left ventricular pressure-volume areas and
±dP/dtmax values of untreated rats with aortic
constriction reflected the enhanced performance of ventricles
with a greater muscle mass. However, derived indices of myocardial
performance, that is, normalized stress-length area (Table 1
and Fig 1B) and maximal rates of wall stress rise and decline (Fig 2, C
and D), were reduced. By contrast, the etomoxir treatment increased
these parameters. A significant interaction (two-way ANOVA)
between pressure overload and etomoxir treatment was observed for
-d/dtmax but not +d/dtmax or
stress-length area. As a consequence, the etomoxir treatment improved
-d/dtmax more markedly than +d/dtmax or
stress-length area.
The left ventricular pressure overload decreased the
proportion of myosin V1 and correspondingly increased the
proportion of myosin V3 (Table 2). The etomoxir treatment had an
opposite effect: it increased the myosin V1 proportion and
decreased the myosin V3 proportion (Table 2). A significant
interaction (two-way ANOVA) between pressure overload and etomoxir
treatment was observed for the myosin isozymes proportion, indicating
that etomoxir affected specifically myosin alterations induced by left
ventricular pressure overload.
|
The percentage of -MHC correlated significantly with derived
parameters of myocardial performance, that is,
stress-length area as well as rates of wall stress rise and decline
(Fig 3, B, D, and F). The dependence of
ventricular function on both ventricular mass
and myosin isozymes became apparent when relationships between
parameters of ventricular function and the
proportion of -MHC were assessed. No significant correlation was
observed when all groups were combined. By contrast, when groups with
comparable ventricular weight, that is, sham-operated or
pressure-overloaded rats, were analyzed, the proportion of
-MHC was correlated (P<.001) both with pressure-volume
area and ±dP/dtmax. Two separate regression lines could be
identified. One regression line for sham-operated rats and one for rats
with aortic constriction (Fig 3, A, C, and E). When the effect of
ventricular mass was taken into account by transforming
the pressure-volume area into stress-length area and the
±dP/dtmax values into ±d/dtmax values, the
two separate regression lines merged into one (Fig 3, B, D, and F).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The increase in the pressure-volume area and higher rates of pressure rise and decline of untreated pressure-overloaded left ventricles are signs of improved pump performance. A more thorough analysis demonstrates, however, specific defects at the myocardial level. To account for effects of ventricular mass and chamber volume on ventricular pump performance and to assess myocardial function, developed pressure was normalized by calculating mean wall stress and end-diastolic volume by calculating normalized midwall circumference. The transformation of the pressure-volume area and ±dP/dtmax values into stress-length area and ±d
/dtmax values revealed a depressed myocardial
function of overloaded left ventricles (Figs 1 and 2 and Table 1).
The two different correlation lines between indices of
ventricular function and -MHC proportion for the
hypertrophied and nonhypertrophied ventricles also demonstrate that
pump function is affected both by ventricular as well as
myocardial parameters. Although the indices of
ventricular function were increased in overloaded left
ventricles despite decreased -MHC proportion, the values were lower
than those that would be extrapolated for hypertrophied ventricles with
an extrapolated -MHC proportion of 60% to 80%. These values were
partially reached after etomoxir treatment (Fig 3, A, C, and E).
Etomoxir improved left ventricular as well as myocardial
performance without inducing a significant additional left
ventricular hypertrophy. It is therefore
plausible that the etomoxir treatment partially reversed the
derangement underlying the decreased myocardial performance. By
contrast, the modest enhancement of stress-length area and
±d/dtmax values of sham-operated etomoxir-treated rats
indicates that the observed improved left ventricular
performance was only partially due to an enhanced myocardial
performance and that the increased left ventricular
mass had a contributing effect.
The mechanisms by which the etomoxir improved myocardial
performance are not fully understood. Inhibitors of
CPT-1 have no immediate effects on cardiac performance in
control animals.21 It is therefore unlikely that the
improvement of left ventricular function observed in this
study is a consequences of acute metabolic alterations
caused by CPT-1 inhibition. There is, however, increasing evidence that
etomoxir improves left ventricular performance by
phenotypic modification of hypertrophied ventricles. A chronic CPT-1
inhibition induced not only moderate cardiac hypertrophy
but also increased -MHC expression.13 14 15 16 17 The effect of
etomoxir on cardiac isomyosins and SR were more pronounced in
functional states characterized by a reduced isomyosin V1
proportion and related SR parameters.15 17
This is confirmed in the present study, in which etomoxir treatment
is shown to increase significantly the proportion of isomyosin
V1 of overloaded hearts but not of control hearts (Table 2). Limited effect of etomoxir on V1 proportion in
sham-operated rats may be related to the high initial percentage of
V1 isomyosin in these young animals. A coordinated action
on both myosin isoenzymes and SR maybe responsible for the modest
enhancement of myocardial performance in etomoxir treated
sham-operated rats.15
The significant correlation between the indices of left
ventricular or myocardial performance and the
percentage of -MHC (Fig 3) demonstrates an important influence of
MHC on left ventricular performance. The question
arises whether the observed correlation is causal or not. A number of
studies have suggested that ventricular and myocardial
function may be related to myosin isozyme
composition.10 22 23 A higher proportion of -MHC is
expected to increase the rate of cross-bridge cycling, and one could
infer an increased rate of pressure rise7 but also
increased rate of pressure decline.24 Enhanced developed
pressures are typically related to a greater availability of
activator calcium and faster relaxation to an increased
rate of activator calcium removal.25 In the
present study, the -MHC proportion was correlated with indices
that characterize both contraction and relaxation (Fig 3). It thus
appears that the changes in the -MHC percentage after etomoxir
treatment might also be associated with alterations in the activity of
organelles responsible for the activator calcium
cycling.
Similar to etomoxir, enhanced thyroid influences increased the
proportion of myosin V1 that was associated with positive
inotropic and lusitropic effects.10 Vice versa, in
hypothyroidism, in which ß-MHC predominates, contraction and
relaxation were slowed.7 10 It should be pointed out that
the present experiments were not designed to identify molecular
processes involved in the improved function of overloaded hearts
arising from etomoxir treatment. The study nonetheless supports the
contention that the partial prevention of a decrease in -MHC
accounts for the improvement of left ventricular
performance.
In the present approach, evaluation of isovolumic contractions was preferred to distinguish myocardial and ventricular determinants of pump function of hypertrophied left ventricles. It was thus not possible to assess the influence of etomoxir treatment on left ventricular ejection. Other limitations relate to nonsimultaneous pressure and volume measurements, exclusion of right ventricular influences, assumptions on left ventricular geometry, and physical properties of the myocardium required for converting pressure-volume data to stress-strain data. Despite these limitations, the present comparative study clearly demonstrates that treatment with etomoxir improves myocardial function in rats with chronic left ventricular pressure overload. Since additional hypertrophy was absent in pressure-overloaded left ventricles after etomoxir treatment, this novel conclusion can be derived from directly measured values, ie, developed pressure and ±dP/dtmax, which do not involve transformations. A noteworthy finding was that the small dose of etomoxir used (15 mg/kg per day racemic form equivalent to 7.5 mg/kg per day of biologically active enantiomeric (+)-etomoxir) induced an improvement of left ventricular function that occurred independent of hypertrophy. In accordance, it was previously shown that 5 mg/kg per day enantiomeric (+)-etomoxir increased rate of SR Ca2+ uptake but not left ventricular weight,13 whereas higher doses resulted in cardiac hypertrophy.14 15 16 17 Further work is required to assess to what extent the present etomoxir treatment interfered with endogenous changes in fuel metabolism of hypertrophied hearts.26 27 28
Indices of ventricular function depend also on heart rate and ventricular load. It is, however, unlikely that these variables significantly influenced the present results. The overall frequency of isovolumic contractions was 329±22 (bpm), with no significant differences within experimental groups. Furthermore, the differences in functional parameters were detected over the whole range of physiologically encountered preload values. Since the evaluated contractions were isovolumic (with the exception of coronary flow), the afterload was maximal for a given preload.
In conclusion, long-term treatment with etomoxir improved the myocardial performance and thereby the functional capacity of pressure-overloaded left ventricle. Chronic CPT-1 inhibition may therefore represent a novel avenue for preventing undesirable consequences of pressure overload–induced cardiac hypertrophy.
|
Acknowledgments |
|---|
The study was supported by the Deutsche Forschungsgemeinschaft (Ja 172/14-1, Ru 245/6-2), the Alfred-Teufel- Stiftung, and the Slovak Grant Agency No. 1/4114/97 and 1/4133/97. The experimental part of this study was performed at the Institute of Physiology II, University of Tübingen, Germany.
Received April 10, 1997; revision received June 27, 1997; accepted July 15, 1997.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Katz AM. Changing strategies in the management of heart failure. J Am Coll Cardiol.. 1989;13:513-523.[Abstract]
2. Schwartz K, Bouveret P, Bercovici J, Swynghedauw B. An immunochemical difference between myosins from normal and hypertrophied rat hearts. FEBS Lett.. 1978;93:137-139.[Medline] [Order article via Infotrieve]
3. Izumo S, Lompre AM, Matsuoka R, Koren G, Schwartz K. Myosin heavy chain messenger RNA and protein isoform transitions during cardiac hypertrophy: interaction between hemodynamic and thyroid hormone-induced signals. J Clin Invest.. 1987;79:970-977.
4. Chien KR, Knowlton KU, Zhu H, Chien S. Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response. FASEB J.. 1991;5:3037-3046.[Abstract]
5. Lompré AM, Anger M, Levitsky D. Sarco(endo)plasmic reticulum calcium pumps in the cardiovascular system: function and gene expression. J Mol Cell Cardiol.. 1994;26:1109-1121.[Medline] [Order article via Infotrieve]
6. Schwartz K, Carrier L, Mercadier JJ, Lompre AM, Boheler KR. Molecular phenotype of the hypertrophied and failing myocardium. Circulation. 1993;87(suppl VII):VII-5-VII-10.
7. Ebrecht G, Rupp H, Jacob R. Alteration of mechanical parameters in chemically skinned preparation of rat myocardium as a function of isoenzyme pattern of myosin. Basic Res Cardiol.. 1982;77:220-234.[Medline] [Order article via Infotrieve]
8. Alpert NR, Mulieri LA. Heat mechanics and myosin ATPase in normal and hypertrophied heart muscle. Fed Proc.. 1982;41:192-198.[Medline] [Order article via Infotrieve]
9. Katz AM. Cardiomyopathy of overload: a major determinant of prognosis in congestive heart failure. N Engl J Med.. 1990;322:100-110.[Medline] [Order article via Infotrieve]
10. Morkin E, Flink IL, Goldman S. Biochemical and physiologic effects of thyroid hormone on cardiac performance. Prog Cardiovasc Dis.. 1983;25:435-464.[Medline] [Order article via Infotrieve]
11.
Gay RG, Graham S, Aquirre M, Goldman S, Morkin E.
Effects of 10-12 days treatment with L-thyroxine in rats with
myocardial infarction. Am J Physiol.. 1988;255:H801–H806.
12.
Penncock GD, Raya TE, Bahl JJ, Goldman S, Morkin E.
Combination treatment with captopril and the thyroid hormone
analogue 3,5-diiodothyropropionic acid (DITPA): a new approach to
improving left ventricular performance in heart
failure. Circulation.. 1993;88:1289-1298.
13.
Rupp H, Wahl R, Hansen M. Influence of diet and
carnitine palmitoyltransferase I inhibition on myosin and sarcoplasmic
reticulum. J Appl Physiol.. 1992;72:352-360.
14. Rupp H, Elimban V, Dhalla NS. Modification of subcellular organelles in pressure-overloaded heart by etomoxir, a carnitine palmitoyltransferase I inhibitor. FASEB J.. 1992;6:2349-2353.[Abstract]
15.
Vetter R, Rupp H. CPT-1 inhibition by etomoxir
has a chamber-related action on cardiac sarcoplasmic reticulum and
isomyosins. Am J Physiol.. 1994;267:H2091–H2099.
16.
Rupp H, Schulze W, Vetter R. Dietary
medium-chain triglycerides can prevent changes in myosin
and SR due to CPT-1 inhibition by etomoxir. Am J
Physiol.. 1995;269:R630–R640.
17. Zarain-Herzberg A, Rupp H, Elimban V, Dhalla NS. Modification of sarcoplasmic reticulum gene expression in pressure overloaded cardiac hypertrophy by etomoxir. FASEB J.. 1996;10:1303-1309.[Abstract]
18. Jacob R, Brändle M, Dierberger B, Ross Ch. Conceptional and methodological basis for the evaluation of ventricular and myocardial mechanics. In: Jacob R, ed. Evaluation of Cardiac Contractility. Stuttgart/New York, NY: Gustav Fischer; 1990:75-100.
19. Hepp A, Hansis M, Gülch R, Jacob R. Left ventricular isovolumetric pressure-volume relations, "diastolic tone," and contractility in the heart after physical training. Basic Res Cardiol.. 1974;69:517-531.
20.
Sandler H, Dodge HT. Left
ventricular tension and stress in man. Circ
Res.. 1963;13:91-104.
21.
Bressler R, Corredor C, Brendel K. Hypoglycin
and hypoglycin-like compounds. Pharmacol Rev.. 1982;21:105-130.
22. Jacob R, Brändle M, Dierberger B, Rupp H. Functional consequences of cardiac hypertrophy and dilatation. Basic Res Cardiol. 1991;86(suppl 1):114-130.
23.
Winegrad S. Regulation of cardiac contractile
proteins; correlations between physiology and biochemistry.
Circ Res.. 1984;55:565-574.
24.
Brutsaert DL, Sys SU. Relaxation and
diastole of the heart. Physiol Rev.. 1989;69:1228-1315.
25.
Callewaert G. Excitation-contraction coupling in
mammalian cardiac cells. Cardiovasc Res.. 1992;26:923-932.
26.
Allard MF, Schonekess BO, Henning SL, English DR,
Lopaschuk GD. Contribution of oxidative metabolism
and glycolysis to ATP production in hypertrophied
heart. Am J Physiol.. 1994;267:H742–H750.
27.
Cunningham MJ, Apstein CS, Weinberg EO, Vogel WM,
Lorell BH. Influence of glucose and insulin on the exaggerated
diastolic and systolic dysfunction of hypertrophied
rat hearts during hypoxia. Circ Res.. 1990;66:406-415.
28.
Massie BM, Schaefer S, Garcia J, McKirnan D, Schwartz
GG, Wisneski JA, Weiner MW, White FC. Myocardial high-energy
phosphate and substrate metabolism in swine with moderate
left ventricular hypertrophy.
Circulation.. 1995;91:1814-1823.
This article has been cited by other articles:
 |
|
 |
|
  P. Alter, H. Rupp, and B. Maisch Assessment and relevance of ventricular wall stress in heart failure Eur. Heart J., September 2, 2008; 29(18): 2316 - 2316. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Doenst, H. Bugger, M. Schwarzer, G. Faerber, M. A. Borger, and F. W. Mohr Three good reasons for heart surgeons to understand cardiac metabolism Eur. J. Cardiothorac. Surg., May 1, 2008; 33(5): 862 - 871. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Sharma, P. Dhillon, R. Wambolt, H. Parsons, R. Brownsey, M. F. Allard, and J. H. McNeill Metoprolol improves cardiac function and modulates cardiac metabolism in the streptozotocin-diabetic rat Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1609 - H1620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Lee, J. Horowitz, and M. Frenneaux Metabolic manipulation in ischaemic heart disease, a novel approach to treatment Eur. Heart J., April 2, 2004; 25(8): 634 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Barbato, S. J. Lee, L. G. Koch, and G. T. Cicila Myocardial function in rat genetic models of low and high aerobic running capacity Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2002; 282(3): R721 - R726. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. N. Sabbaha and W. C. Stanley Partial fatty acid oxidation inhibitors: a potentially new class of drugs for heart failure Eur J Heart Fail, January 1, 2002; 4(1): 3 - 6. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||